Add to ORKGThe manuscripts included in this special issue of Cancer Biotherapy & Radiopharmaceuticals highlight current data and theoretical foundations regarding dose–response relationships related t
Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while...
Purpose: To model dose-response relationships for in vivo experiments with radiolabelled peptides en...
Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in ...
Renal toxicity associated with small-molecule radionuclide ther-apy has been shown to be dose-limiti...
Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequen...
PURPOSE: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequen...
Nuclear medicine is a medical specialty, where diagnostic and or therapeutic radioisotopes are used ...
This article discusses the model of biokinetics of radiopharmaceuticals used for radionu-clide diagn...
Metastatic disease requires a systemic approach to therapy. Alpha particle radiopharmaceutical thera...
PURPOSE: Peptide receptor radionuclide therapy (PRRT) delivers high absorbed doses to kidneys and ma...
Small radiolabeled molecules are finding increasing clinical use for targeted radionuclide therapy. ...
The potential of targeted radionuclide therapy may be limited if the antibody affinity to the tumor ...
D ow nloaded from 2 A number of cancer therapy agents are cleared by the kidney and may affect renal...
Peptide receptor radionuclide therapy (PRRT) has been constantly evolving over the last decade, prov...
Use rationally the Red Marrow (RM) and Whole Body (WB) dosimetry pre and during therapy in Different...
Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while...
Purpose: To model dose-response relationships for in vivo experiments with radiolabelled peptides en...
Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in ...
Renal toxicity associated with small-molecule radionuclide ther-apy has been shown to be dose-limiti...
Purpose: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequen...
PURPOSE: A study was designed to define the therapeutic efficacy, safety, and toxicity of two sequen...
Nuclear medicine is a medical specialty, where diagnostic and or therapeutic radioisotopes are used ...
This article discusses the model of biokinetics of radiopharmaceuticals used for radionu-clide diagn...
Metastatic disease requires a systemic approach to therapy. Alpha particle radiopharmaceutical thera...
PURPOSE: Peptide receptor radionuclide therapy (PRRT) delivers high absorbed doses to kidneys and ma...
Small radiolabeled molecules are finding increasing clinical use for targeted radionuclide therapy. ...
The potential of targeted radionuclide therapy may be limited if the antibody affinity to the tumor ...
D ow nloaded from 2 A number of cancer therapy agents are cleared by the kidney and may affect renal...
Peptide receptor radionuclide therapy (PRRT) has been constantly evolving over the last decade, prov...
Use rationally the Red Marrow (RM) and Whole Body (WB) dosimetry pre and during therapy in Different...
Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while...
Purpose: To model dose-response relationships for in vivo experiments with radiolabelled peptides en...
Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in ...